DOCSLIB.ORG

Annex 2 Composition of Oral and Injectable Estrogen–Progestogen Contraceptives

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annex 2 Composition of Oral and Injectable Estrogen–Progestogen Contraceptives ANNEX 2 COMPOSITION OF ORAL AND INJECTABLE ESTROGEN–PROGESTOGEN CONTRACEPTIVES Annex 2 lists the composition of brands of estrogen–progestogen preparations used in combined injectables (Table 1), combined oral (Table 2) and phasic oral (Table 3) contraceptives. The countries in which these formulations are used are noted. Are listed only those brands for which availability was reported. The source of these tables is the International Planned Parenthood Foundation (IPPF). Data have been taken from the IPPF 2002 website [http://contraceptive.ippf.org] at the time of the monograph meeting (June 2005). This online site is regularly updated. Table 1. Combined injectables Brand name Composition Countries of availability Acefil Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Agurin Dihydroxyprogesterone acetophenide 150 mg Chile + estradiol enanthate 10 mg Anafertin Dihydroxyprogesterone acetophenide 75 mg El Salvador, Mexico + estradiol enanthate 5 mg Ciclofem Medroxyprogesterone acetate 25 mg Guatemala + estradiol cypionate 5 mg Ciclofemina Medroxyprogesterone acetate 25 mg El Salvador + estradiol cypionate 5 mg Ciclomes Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Ciclovular Dihydroxyprogesterone acetophenide 150 mg Brazil + estradiol enanthate 10 mg Clinomin Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Cyclofem Medroxyprogesterone acetate 25 mg Chile, Indonesia, Malaysia, Mexico, + estradiol cypionate 5 mg Panama, Zimbabwe Cyclofemina Medroxyprogesterone acetate 25 mg Brazil, Costa Rica, Mexico + estradiol cypionate 5 mg Cycloven Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg –431– 432 IARC MONOGRAPHS VOLUME 91 Table 1 (contd) Brand name Composition Countries of availability Deproxone Dihydroxyprogesterone acetophenide 150 mg Dominican Republic, El Salvador, + estradiol enanthate 10 mg Honduras, Panama Ginestest Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Gynomes Dihydroxyprogesterone acetophenide 150 mg El Salvador + estradiol enanthate 10 mg Listen Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Lunelle Medroxyprogesterone acetate 25 mg Puerto Rico, USA + estradiol cypionate 5 mg Mesigyna Norethisterone enanthate 50 mg Argentina, Bahamas, Barbados, + estradiol valerate 5 mg Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Egypt, El Salvador, Ghana, Grenada, Guatemala, Guyana, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, St. Lucia, Turkey, Uruguay, Venezuela Neogestar Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Norigynon Norethisterone enanthate 50 mg Ghana, Kenya, Zimbabwe + estradiol valerate 5 mg Normagest Dihydroxyprogesterone acetophenide 150 mg El Salvador, Honduras, Nicaragua, + estradiol enanthate 10 mg Panama Novafem Medroxyprogesterone acetate 25 mg Chile + estradiol cypionate 5 mg Novular Dihydroxyprogesterone acetophenide 150 mg El Salvador + estradiol enanthate 10 mg Oterol Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Ovoginal Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Perlutal Dihydroxyprogesterone acetophenide 150 mg Argentina, Belize, Mexico, Peru + estradiol enanthate 10 mg Perlutan Dihydroxyprogesterone acetophenide 150 mg Brazil + estradiol enanthate 10 mg Perlutin- Dihydroxyprogesterone acetophenide 150 mg Paraguay Unifarma + estradiol enanthate 10 mg Permisil Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg ANNEX 2 433 Table 1 (contd) Brand name Composition Countries of availability Proter Dihydroxyprogesterone acetophenide 150 mg Costa Rica + estradiol enanthate 10 mg Seguralmes Dihydroxyprogesterone acetophenide 150 mg Chile + estradiol enanthate 10 mg Soluna Dihydroxyprogesterone acetophenide 150 mg Peru + estradiol benzoate 10 mg Topasel Dihydroxyprogesterone acetophenide 150 mg Costa Rica, Dominican Republic, + estradiol enanthate 10 mg Ecuador, El Salvador, Honduras, Nicaragua, Panama, Spain Unigalen Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Uno Ciclo Dihydroxyprogesterone acetophenide 150 mg Brazil + estradiol enanthate 10 mg Vagital Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Yectames Dihydroxyprogesterone acetophenide 75 mg Costa Rica, Dominican Republic, + estradiol enanthate 5 mg El Salvador, Honduras, Mexico, Panama Yectuna Dihydroxyprogesterone acetophenide 120 mg Paraguay + estradiol enanthate 10 mg From IPPF (2002) Table 2. Combined pills Brand name Composition Countries of availability Alesse Levonorgestrel 0.1 mg Canada, USA + ethinylestradiol 20 μg Anfertil Levonorgestrel 0.25 mg Brazil + ethinylestradiol 50 μg Anna Levonorgestrel 0.15 mg Cambodia, Laos, Myanmar, Thailand, Viet + ethinylestradiol 30 μg Nam Anovlar 1mg Norethisterone acetate 1 mg Egypt, Iraq, Morocco + ethinylestradiol 50 μg Anovulatorios Levonorgestrel 0.15 mg Chile Microdosis + ethinylestradiol 30 μg Anuar Cyproterone acetate 2 mg Chile + ethinylestradiol 35 μg Anulette 20 Levonorgestrel 0.1 mg Chile + ethinylestradiol 20 μg 434 IARC MONOGRAPHS VOLUME 91 Table 2. Combined pills Brand name Composition Countries of availability Anulette C.D. Levonorgestrel 0.15 mg Chile + ethinylestradiol 30 μg Anulette Levonorgestrel 0.15 mg Chile, Peru + ethinylestradiol 30 μg Anulit Levonorgestrel 0.15 mg Paraguay + ethinylestradiol 30 μg April Levonorgestrel 0.1 mg Uruguay + ethinylestradiol 20 μg Belara Chlormadinone acetate 2 mg Ecuador, Germany + ethinylestradiol 30 μg Brenda 35 Cyproterone acetate 2 mg Australia + ethinylestradiol 35 μg Brevicon Norethisterone 0.5 mg Puerto Rico, St. Lucia, USA + ethinylestradiol 35 μg Brevicon 0.5 + 35 Norethisterone 0.5 mg Canada + ethinylestradiol 35 μg Brevicon 1+35 Norethisterone 1 mg Canada + ethinylestradiol 35 μg Brevicon 20 Norethisterone 0.5 mg Mexico + ethinylestradiol 35 μg Brevinor Norethisterone 0.5 mg Australia, Hong Kong, Ireland, Malaysia, + ethinylestradiol 35 μg Malta, Mauritius, New Zealand, South Africa, Sudan, United Kingdom Brevinor-1 Norethisterone 1 mg Australia + ethinylestradiol 35 μg Ciclidon Desogestrel 0.15 mg Chile + ethinylestradiol 30 μg Ciclidon 20 Desogestrel 0.15 mg Chile + ethinylestradiol 20 μg Ciclo 21 Levonorgestrel 0.15 mg Brazil + ethinylestradiol 30 μg Ciclomex Gestodene 0.075 mg Chile + ethinylestradiol 30 μg Ciclomex 20 Gestodene 0.075 mg Chile + ethinylestradiol 20 μg Ciclon Levonorgestrel 0.15 mg Brazil + ethinylestradiol 30 μg ANNEX 2 435 Table 2 (contd) Brand name Composition Countries of availability Cilest Norgestimate 0.25 mg + Argentina, Armenia, Aruba, Austria, ethinylestradiol 35 μg Barbados, Belgium, Bermuda, Bolivia, Bulgaria, Colombia, Costa Rica, Cyprus, Czech Republic, Denmark, Dominican Republic, Egypt, El Salvador, Estonia, Finland, France, Germany, Guatemala, Honduras, Hungary, Ireland, Israel, Italy, Jamaica, Kuwait, Latvia, Lithuania, Luxembourg, Macedonia, Mexico, Netherlands, Netherlands Antilles, Nicaragua, Norway, Panama, Paraguay, Poland, Qatar, Romania, Russia, Slovak Republic, Slovenia, Spain, Sudan, Sweden, Switzerland, Trinidad and Tobago, United Arab Emirates, United Kingdom, Uruguay, Yugoslavia Conceplan M Norethisterone 0.5 mg Germany + ethinylestradiol 30 μg Confiance Levonorgestrel 0.15 mg Côte D’Ivoire + ethinylestradiol 30 μg Conova Ethynodiol diacetate 2 mg Bermuda + ethinylestradiol 30 μg Conova 30 Ethynodiol diacetate 2 mg Belgium, Luxembourg, Malawi, St. Vincent + ethinylestradiol 30 μg and the Grenadines, Tanzania, Trinidad and Tobago Cycleane 30 Desogestrel 0.15 mg Djibouti, France + ethinylestradiol 30 μg Cycleane-20 Desogestrel 0.15 mg France + ethinylestradiol 20 μg Demulen Ethynodiol diacetate 1 mg Russia, Trinidad and Tobago + ethinylestradiol 50 μg Demulen 1/35 Ethynodiol diacetate 1 mg Jamaica, Netherlands Antilles, Puerto Rico, + ethinylestradiol 35 μg USA Demulen 1/50 Ethynodiol diacetate 1 mg Russia, USA + ethinylestradiol 50 μg Demulen 30 Ethynodiol diacetate 2 mg Canada, Puerto Rico + ethinylestradiol 30 μg Denoval Levonorgestrel 0.25 mg Belize, Dominican Republic, El Salvador, + ethinylestradiol 50 μg Guatemala, Honduras, Nicaragua Denoval-Wyeth Levonorgestrel 0.25 mg Costa Rica + ethinylestradiol 50 μg Desmin 20 Desogestrel 0.15 mg Germany + ethinylestradiol 20 μg 436 IARC MONOGRAPHS VOLUME 91 Table 2 (contd) Brand name Composition Countries of availability Desmin 30 Desogestrel 0.15 mg Germany + ethinylestradiol 30 μg Desogen Desogestrel 0.15 mg USA + ethinylestradiol 30 μg Desolett Desogestrel 0.15 mg Sweden, Turkey + ethinylestradiol 30 μg Desoran Desogestrel 0.15 mg Chile + ethinylestradiol 30 μg Desorelle Desogestrel 0.15 mg Denmark, Romania + ethinylestradiol 30 μg Desoren 20 Desogestrel 0.15 mg Chile + ethinylestradiol 20 μg Diane Cyproterone acetate 2 mg Albania, Armenia, Australia, Azerbaijan, + ethinylestradiol 35 μg Bahrain, Barbados, Belarus, Belgium, Bermuda, Brazil, Bulgaria, Canada, Colombia, Croatia, Cyprus, Czech Republic, Egypt, France, Georgia, Germany, Hungary, Ireland, Israel, Italy, Jordan, Kazakhstan, Kenya, Kuwait, Kyrgyzstan, Lebanon, Luxembourg, Macedonia, Malawi, Malaysia, Malta, Mauritius, Mexico, Moldova, Morocco, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Peru, Philippines, Poland, Portugal, Qatar, Romania, Russia, Saudi Arabia, Singapore, Slovak Republic, Slovenia, South Africa, Spain, Sri Lanka, St. Lucia, Sweden, Switzerland,
Load more

Recommended publications
  • Emperor Hirohito (1)” of the Ron Nessen Papers at the Gerald R
    The original documents are located in Box 27, folder “State Visits - Emperor Hirohito (1)” of the Ron Nessen Papers at the Gerald R. Ford Presidential Library. Copyright Notice The copyright law of the United States (Title 17, United States Code) governs the making of photocopies or other reproductions of copyrighted material. Ron Nessen donated to the United States of America his copyrights in all of his unpublished writings in National Archives collections. Works prepared by U.S. Government employees as part of their official duties are in the public domain. The copyrights to materials written by other individuals or organizations are presumed to remain with them. If you think any of the information displayed in the PDF is subject to a valid copyright claim, please contact the Gerald R. Ford Presidential Library. Digitized from Box 27 of The Ron Nessen Papers at the Gerald R. Ford Presidential Library THE EMPEROR OF JAPAN ~ . .,1. THE EMPEROR OF JAPAN A Profile On the Occasion of The Visit by The Emperor and Empress to the United States September 30th to October 13th, 1975 by Edwin 0. Reischauer The Emperor and Empress of japan on a quiet stroll in the gardens of the Imperial Palace in Tokyo. Few events in the long history of international relations carry the significance of the first visit to the United States of the Em­ peror and Empress of Japan. Only once before has the reigning Emperor of Japan ventured forth from his beautiful island realm to travel abroad. On that occasion, his visit to a number of Euro­ pean countries resulted in an immediate strengthening of the bonds linking Japan and Europe.
    [Show full text]
  • Energy Efficiency And
    Progress with The Energy Policy Review: A Perspective OIES Seminars 7 October 2003 John Bower Overview What the White Paper Said Reality Dawns An alternative 20:20 Vision John Bower Progress on UK Energy White Paper 2 What the White Paper Said UKEWP refocused energy policy away from a UK driven liberalisation agenda… GOALS AND POLICIES 1. Reduce CO2 emissions by 60% by 2050 Reduce amount of energy we consume Central to future market and policy will be emissions trading Raise efficiency standards in home appliances and housing Encourage low carbon fuels and renewables through grants and subsidy 2. Maintain reliability of energy supplies Right infrastructure / regulatory systems in UK and liberalisation of Europe Pursue regional stability and economic reform in producing areas Promote understanding of markets and conditions for FDI in producing areas Forward prices will signal the need for investment Improve contingency planning in dealing with major incidents John Bower Progress on UK Energy White Paper 3 What the White Paper Said …. towards an EU driven multifaceted agenda GOALS AND POLICIES 3. Promote competitive markets in UK and beyond Raise rate of sustainable economic growth Support business and competitiveness through reliable / affordable energy Encourage firms to innovate, reduce cost, deliver better goods and services Use market based instruments to deliver policy goals Work with business to prepare them for the low carbon economy of the future 4. Ensure that every home is adequately and affordably heated Reduce poverty by lowering prices and raising social security payments Improve quality of housing stock via insulation and energy efficiency grants John Bower Progress on UK Energy White Paper 4 What the White Paper Said UKEWP relied on carbon trading and uneconomic/unproven technology… ENERGY SYSTEM IN 2020 1.
    [Show full text]
  • MI4A Vaccine Purchase Data for Countries This Note Is Intended to Guide Countries in Their Use of the MI4A Vaccine Purchase Data
    MI4A Vaccine Purchase Data for Countries This note is intended to guide countries in their use of the MI4A vaccine purchase data. What data is available? new vaccine introductions, but also for product switches – and to understand the status of product The WHO vaccine market intelligence database registrations. Fifty-six Member States responded compiles vaccine purchase (product, price and to these new questions. procurement) data as reported by countries via the WHO/UNICEF Joint Reporting Form (JRF) over the This information is essential to WHO’s efforts to period of 2013–2018. While country names are not improve global market forecasts and inform displayed, data is publicly available on the MI4A suppliers’ and global policy-makers’ investment website and provides information by country decisions. WHO encourages all countries to characteristics (e.g. region, income group…) by report information on new introduction plans and vaccine and by year of purchase, along with price planned product changes as well as to respond to per dose (USD), procurement mechanism and questions related to registration. annual volumes. 1 The number of countries reporting vaccine How can my country use this data? purchase data through the JRF continues to Countries can use the vaccine purchase data in increase year after year, with 182 Member States several different ways, such as to: (93%) reporting some vaccine procurement information in 2019 – including 158 (81%) fully • Understand how the price of vaccines in their reporting on vaccine purchase data. Price reporting immunization schedule relate to other this year marks a 3% increase from last year and products on the market, or compare the more than triple the reporting from 2016.
    [Show full text]
  • Contribution of Podoviridae and Myoviridae Bacteriophages
    www.nature.com/scientificreports OPEN Contribution of Podoviridae and Myoviridae bacteriophages to the efectiveness of anti‑staphylococcal therapeutic cocktails Maria Kornienko1*, Nikita Kuptsov1, Roman Gorodnichev1, Dmitry Bespiatykh1, Andrei Guliaev1, Maria Letarova2, Eugene Kulikov2, Vladimir Veselovsky1, Maya Malakhova1, Andrey Letarov2, Elena Ilina1 & Egor Shitikov1 Bacteriophage therapy is considered one of the most promising therapeutic approaches against multi‑drug resistant bacterial infections. Infections caused by Staphylococcus aureus are very efciently controlled with therapeutic bacteriophage cocktails, containing a number of individual phages infecting a majority of known pathogenic S. aureus strains. We assessed the contribution of individual bacteriophages comprising a therapeutic bacteriophage cocktail against S. aureus in order to optimize its composition. Two lytic bacteriophages vB_SauM‑515A1 (Myoviridae) and vB_SauP‑ 436A (Podoviridae) were isolated from the commercial therapeutic cocktail produced by Microgen (Russia). Host ranges of the phages were established on the panel of 75 S. aureus strains. Phage vB_ SauM‑515A1 lysed 85.3% and vB_SauP‑436A lysed 68.0% of the strains, however, vB_SauP‑436A was active against four strains resistant to vB_SauM‑515A1, as well as to the therapeutic cocktail per se. Suboptimal results of the therapeutic cocktail application were due to extremely low vB_SauP‑436A1 content in this composition. Optimization of the phage titers led to an increase in overall cocktail efciency. Thus, one of the efective ways to optimize the phage cocktails design was demonstrated and realized by using bacteriophages of diferent families and lytic spectra. Te wide spread of multidrug-resistant (MDR) bacterial pathogens is recognized by the World Health Organi- zation (WHO) as a global threat to modern healthcare1.
    [Show full text]
  • List of Registred Drugs in Armenia (01.03.2017-31.03.2017)
    LIST OF REGISTRED DRUGS IN ARMENIA (01.03.2017-31.03.2017) International nonproprietary name Dose and Registration Term of Legal Status N Trade name Drug form Manufacturer Country ATC1 code License holder (generic) or active packaging number registration for Supply ingredients name Eli Lilly Regional Lilly France S.A.S., Operations GmbH., solution for 100IU/ml, Zone Industrielle, 2 17.03.2017 1 Abasaglar insulin glargine France A10AE04 16535 PoM2 Koelblgasse 8-10, injection 3ml cartridges (5) rue du Colonel Lilly, 17.03.2022 1030, Vienna, 67640 Fegersheim Austria Olainfarm JSC, 5 300mg, Olainfarm JSC, 5 06.03.2017 Rupnicu Str., 2 Adaptol mebicar capsules hard in blister (20/2x10/, Rupnicu Str., Olaine, Latvia N06BX21 16440 PoM 06.03.2022 Olaine, LV-2114, 30/3x10/, 40/4x10/) LV-2114 Latvia Olainfarm JSC, 5 Olainfarm JSC, 5 500mg, 06.03.2017 Rupnicu Str., 3 Adaptol mebicar tablets Rupnicu Str., Olaine, Latvia N06BX21 16441 PoM in blister (20/2x10/) 06.03.2022 Olaine, LV-2114, LV-2114 Latvia 10mg, Pharmstandard- OTCPharm PJSC, fabomotizole in blisters Leksredstva JSC, 27.03.2017 123317, Moscow, 4 Afobazol (fabomotizole tablets (30/1x30/, 60/3x20/, 305022, Kursk, Russia N05BX04 14729/2 PoM 30.07.2020 Testovskaya str., 10, dihydrochloride) 60/2x30/, 90/3x30/, Agregatnaya 2nd str., Russia 120/4x30/) 1a/18 Gedeon Richter 15mg/g, Gedeon Richter PLC, 17.03.2017 PLC, Gyomroi ut 5 Airtal aceclofenac cream 60g aluminium Gyomroi ut 19-21, Hungary M01AB16 16514 OTC3 17.03.2022 19-21, 1103 tube 1103 Budapest Budapest, Hungary 1 Gedeon Richter PLC, Gyomroi ut 19-21, 1103 Budapest - batch releaser, Industrias Gedeon Richter Farmaceuticas powder for oral 100mg, 17.03.2017 PLC, Gyomroi ut 6 Airtal aceclofenac Almirall S.L., Ctra.
    [Show full text]
  • Vaccine Purchase Data and Cover Note for Countries
    MI4A Vaccine Purchase Data for Countries The MI4A Vaccine Purchase How can my country use this data?1 Database What data is available? • • • • WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 1 Immunization Agenda IA 2030 Reporting Vaccine Purchase Data Documenting use of MI4A data WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 2 Key messages to countries • • • 7 WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 3 • • • • • . / WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 4 • • • • • • • 12 WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 5 • • • • • • • • 13 WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 6 • • • • • WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 7 What is MI4A? • • • WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 8 A. Available Products List - as known to WHO The MI4A Products List provides a snapshot overview of vaccine products available for procurement – irrespective of their WHO prequalification status – as of November 2020. This list reflects information reported by countries through the 2020 Joint Reporting Form (JRF) and is supplemented with available information gathered through separate consultations. As part of the MI4A project, WHO conducts in-depth global market studies where the list of available vaccines can be considered comprehensive and up to date. Studies conducted so far include BCG, D&T-containing, measles-containing, meningococcal, HPV, pneumococcal, rabies, and typhoid vaccines. For all the other vaccines it should be noted that this list may not be complete and may be missing some products whose availability is not documented through public reported data and sources.
    [Show full text]
  • Biotechnology in Russia: Why Is It Not a Success Story?
    Biotechnology in Russia: Why is it not a success story? Biotechnology inRussia:Whyisitnotasuccessstory? ROGER ROFFEY Biotechnology in Russia: Why is it not a success story? According to President Medvedev 2009 ‘By and large, our industry continues to make the same outdated products and, as a rule, imported generics from substances bought abroad. There is practically no work to create original medicines and technologies.’…‘We must begin the modernisation and technological upgrading of our entire industrial sector. I see this as a question of our country’s survival in the modern world’… ‘These are the key tasks for placing Russia on a new technological level and making it a global leader’. Many states including Russia see biotechnology and its commercialization as a key driver for their future growth. The biotechnology area is characterized by being a very knowledge-intensive activity where there is increasing global competition for know-how. Russia had a very good historical base of R&D and know- how in biotechnology from the previous Soviet military programme. There have been many attempts since 2000 to revive the Russian biotechnology industry not least in 2005 but without much success. In 2009 there were again very ambitious programmes and strategies developed as well as techno-parks for the ROGERROFFEY development of the biotechnology and pharmaceuticals industry up to 2020. It has also been announced by President Medvedev the creation of a Russian equivalent to ‘Silicon Valley’ to include R&D also in biotechnology outside Moscow. There have been many such grand plans but so far they have not been very successful and the question for this study was if it would be different this time? Why are scientists still leaving Russia and foreign investors still hesitating to invest in Russian biotechnology or pharmaceuticals? Why is Russia still not able to compete on the global biotechnology market and is ranked only as number 70 in the world? The current problems and prospects for the biotechnology and pharmaceuticals industries are analysed.
    [Show full text]
  • World Bank Document
    WDP-89 Public Disclosure Authorized World Bank Discussion Papers AfricaTechnical Department Series Implementing Public Disclosure Authorized Educational Policies in Utganda Public Disclosure Authorized Cooper F. Odaet Public Disclosure Authorized V. & r ''k Recent World Bank Discussion Papers No. 32 Tenancy in South Asia. Inderjit Singh No. 33 Land and Labor in South Asia. lnderjit Singh No. 35 Global Trends in Real ExchiangeRates. Adrian Wood No. 36 Income Distribution and Economic Development in Malawi: Some Historical Perspectives.Frederic L. Pryor No. 37 Income Distribution and Economic Development in Madagascar:Some Historical Perspectives.Frederic L. Pryor No. 38 Quality Controls of Traded Commodities and Services in DevelopinigCountries. Simon Rottenberg and Bruce Yandle No. 39 Livestock Productionin North Africa and the 1MiddleEast: Problemsand Perspectives.John C. Glenn [Also available in French (39F)j No. 40 Nongovernmental Organizations and Local Development. Michael M. Cemea [Also available in Spanish (40S)] No. 41 Patterns of Development: 1950 to 1983. Moises Syrquin and Hollis Chenery No. 42 Voluntary Debt-Reduction Operations: Bolivia, iMexico, and Beyond... Ruben Lamdany No. 43 Fertility in Sub-Saharan Africa: Analysis and Explanation. Susan Cochranc and S.M. Farid No. 44 Adjustment Programsand Social We!fare. Elaine Zuckerman No. 45 Primary School Teachers' Salaries in Sub-Saharan Africa. Manuel Zymelman andJoseph DeStefano No. 46 Education and Its Relation to Economic Growth, Poverty, and Income Distribution: Past Evidence and Further Analysis. Jandhyala B.G. Tilak No. 47 InternationalMacroeconomic Adjustment, 1987-1992. Robert E. King and Helena Tang No. 48 Contract Plans and Public Enterprise Performance.John Nellis [Also available in French (48F)] No. 49 Improving Nutrition in India: Policiesand Programsand Their 1imlpact.
    [Show full text]
  • Country Coding Units
    INSTITUTE Country Coding Units v11.1 - March 2021 Copyright © University of Gothenburg, V-Dem Institute All rights reserved Suggested citation: Coppedge, Michael, John Gerring, Carl Henrik Knutsen, Staffan I. Lindberg, Jan Teorell, and Lisa Gastaldi. 2021. ”V-Dem Country Coding Units v11.1” Varieties of Democracy (V-Dem) Project. Funders: We are very grateful for our funders’ support over the years, which has made this ven- ture possible. To learn more about our funders, please visit: https://www.v-dem.net/en/about/ funders/ For questions: [email protected] 1 Contents Suggested citation: . .1 1 Notes 7 1.1 ”Country” . .7 2 Africa 9 2.1 Central Africa . .9 2.1.1 Cameroon (108) . .9 2.1.2 Central African Republic (71) . .9 2.1.3 Chad (109) . .9 2.1.4 Democratic Republic of the Congo (111) . .9 2.1.5 Equatorial Guinea (160) . .9 2.1.6 Gabon (116) . .9 2.1.7 Republic of the Congo (112) . 10 2.1.8 Sao Tome and Principe (196) . 10 2.2 East/Horn of Africa . 10 2.2.1 Burundi (69) . 10 2.2.2 Comoros (153) . 10 2.2.3 Djibouti (113) . 10 2.2.4 Eritrea (115) . 10 2.2.5 Ethiopia (38) . 10 2.2.6 Kenya (40) . 11 2.2.7 Malawi (87) . 11 2.2.8 Mauritius (180) . 11 2.2.9 Rwanda (129) . 11 2.2.10 Seychelles (199) . 11 2.2.11 Somalia (130) . 11 2.2.12 Somaliland (139) . 11 2.2.13 South Sudan (32) . 11 2.2.14 Sudan (33) .
    [Show full text]
  • 1966 No. 575 the Guyana Independence Order 1966
    135 ST ATUTORY INSTRUMENTS 1966 No. 575 The Guyana Independence Order 1966 Made 16th May 1966 Laid before Parliament Coming into Operation Sections 4 and 13 16th May 1966 Remainder 26th May 1966 At the Court at Buckingham Palace, the 16th day of May 1966 Present, The Queen's Most Excellent Majesty in Council Her Majesty, by virtue and in exercise of the powers vested in Iler by sections 6 and 7 of the Guyana Independence Act 1966(a) and of all other powers enabling Her in that behalf, is pleased, by and with the advice of Her Privy Council, to order, and it is hereby ordtred, as follows:- " 1.-(1) This Order may be cited as the Guyana Independence Citation, commenc:io- Order 1966. ment and (2) Subject to the provisions of sections 4 and 13 of thisOrder , canstructioo. 1 this Order shall l:Ome into operation on 26th May 1966 (in this Order - referred to as " the appointed day"). (3 ) Save where the context otherwise requires, expressions used in sections I to 19 (inclusive) of this Order have the same meanill:g as in the Constitution set out in Schedule 2 to this Order and the provisions of article 125 of that Constitution sha11 apply for the purpose of interpreting those sections as they apply for the purpose of inter­ preting that Constitution. (4) References in article 92 of the said Constitution to any question as to the interpretation of that Constitution shall be construed as in­ cluding references to any question as to the interpretation of any provision of this Order.
    [Show full text]
  • Supreme Court of the United States
    No. 16-136 IN THE Supreme Court of the United States GOVERNMENT OF BELIZE, Petitioner, v. BCB HOLDINGS LIMITED AND BELIZE BANK LIMITED, Respondents. On Petition for a Writ of Certiorari to the United States Court of Appeals for the District of Columbia Circuit AMICUS CURIAE BRIEF OF THE GOVERNMENT OF GUYANA SUPPORTING THE GOVERNMENT OF BELIZE’S PETITION FOR WRIT OF CERTIORARI BENJAMIN G. SHATZ Counsel of Record MANATT, PHELPS & PHILLIPS, LLP 11355 West Olympic Blvd. Los Angeles, CA 90064 [email protected] (310) 312-4000 Counsel for Amicus Curiae The Government of Guyana i TABLE OF CONTENTS BRIEF OF AMICUS CURIAE ..........................1 INTEREST OF AMICUS CURIAE ...................1 SUMMARY OF ARGUMENT ...........................5 REASONS FOR GRANTING THE PETITION .................................................7 I. The CCJ Is Vitally Important To The Caribbean Region’s Goals Of Independence And Solidarity .............7 II. The CCJ’s Opinion In This Case Is Of Utmost Importance Because It Addresses Foundational Issues Of Democratic Government .................. 11 CONCLUSION ................................................ 13 ii TABLE OF AUTHORITIES BCB Holdings Ltd. v. Attorney General of Belize, CCJ Appeal No. CV 7 of 2012 ............... 11–12 New York Convention on the Recognition and Enforcement of Foreign Arbitral Awards, Article V(2)(b) .............................................. 12 1 BRIEF OF AMICUS CURIAE The Government of Guyana submits this brief in support of the Government of Belize’s petition for certiorari.1 INTEREST OF AMICUS CURIAE The Co-operative Republic of Guyana is a sovereign nation on the northern coast of South America, bordering Venezuela, Brazil, Suriname and the Caribbean Sea. Like Belize, Guyana is intimately tied geographically, culturally, historically, linguistically, and politically to the Caribbean region.2 1 Counsel for the Government of Guyana authored this brief in whole and no other person or entity made a monetary contribution to the preparation or submission of this brief.
    [Show full text]
  • Nationalism, Constitutionalism and Sir Ivor Jennings' Engagement with Ceylon
    Edinburgh Research Explorer 'Specialist in omniscience'? Nationalism, constitutionalism and Sir Ivor Jennings' engagement with Ceylon Citation for published version: Welikala, A 2016, 'Specialist in omniscience'? Nationalism, constitutionalism and Sir Ivor Jennings' engagement with Ceylon. in H Kumarasingham (ed.), Constitution-making in Asia: Decolonisation and State-building in the Aftermath of the British Empire. Routledge Studies in the Modern History of Asia, Routledge, Abingdon; New York, pp. 112-136. https://doi.org/10.4324/9781315629797 Digital Object Identifier (DOI): 10.4324/9781315629797 Link: Link to publication record in Edinburgh Research Explorer Document Version: Peer reviewed version Published In: Constitution-making in Asia Publisher Rights Statement: This is an Accepted Manuscript of a book chapter published by Routledge in Constitution-making in Asia: Decolonisation and State-Building in the Aftermath of the British Empire on 31/3/2016, available online: https://www.routledge.com/Constitution-making-in-Asia-Decolonisation-and-State-Building-in-the- Aftermath/Kumarasingham/p/book/9780415734585 General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 01.
    [Show full text]